S. aureus

Researchers in the US and Europe are implementing pathogen sequencing surveillance programs to track infectious diseases within hospitals.

This Week in PNAS

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

Researchers sequenced samples from children with eczema and found that one Saureus strain dominates during severe disease flares, though it varies by patient.

This Week in PNAS

In PNAS this week: ancient Aboriginal Australian mitochondrial genomes, metabolic dynamics of Staphylococcus aureus strains, and more.

This Week in PNAS

In PNAS this week: degenerative myopathy risk in corgis, genes influencing Vibrio parahaemolyticus fitness, and more.

Researchers in the UK have developed a faster way to gauge antibiotic resistance from bacterial genomes.

The service is the first fruit of an earlier collaboration signed between the companies, and BioMérieux plans to expand it to 10 other microbes over the next two years. 

Vela Diagnostics this week announced the CE-IVD launch of its Sentosa SA Direct MRSA/SA PCR test.

NEW YORK (GenomeWeb News) – Becton Dickinson today announced that it has received US Food and Drug Administration clearance to market its new assay for detection of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus DNA directly from nasal swabs.

DxNA, a privately owned St. George, Utah-based molecular diagnostics firm, will acquire privately held Flagstaff, Ariz.-based Pathogene for an undisclosed amount under an agreement inked by the companies this week.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.